<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">V.F.Snegirev Archives of Obstetrics and Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">V.F.Snegirev Archives of Obstetrics and Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Архив акушерства и гинекологии им. В.Ф. Снегирева</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-8726</issn><issn publication-format="electronic">2687-1386</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">497406</article-id><article-id pub-id-type="doi">10.17816/2313-8726-2023-10-2-133-143</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="zh"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Oxidative Metabolism Genes in Ovarian Neoplasms</article-title><trans-title-group xml:lang="ru"><trans-title>Гены оксидативного метаболизма при новообразованиях яичников</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title/></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8243-6339</contrib-id><name-alternatives><name xml:lang="en"><surname>Proskurnina</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Проскурнина</surname><given-names>Елена Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), assistant professor, Chief Researcher</p></bio><bio xml:lang="ru"><p>доктор мед. наук, доцент, главный научный сотрудник</p></bio><email>proskurnina@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7859-6698</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedorova</surname><given-names>Mariya V.</given-names></name><name xml:lang="ru"><surname>Федорова</surname><given-names>Мария Витальевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, obstetrician-gynecologist</p></bio><bio xml:lang="ru"><p>врач акушер-гинеколог</p></bio><email>theklazontag@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5286-516X</contrib-id><name-alternatives><name xml:lang="en"><surname>Savinova</surname><given-names>Ekaterina A.</given-names></name><name xml:lang="ru"><surname>Савинова</surname><given-names>Екатерина Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, research associate</p></bio><bio xml:lang="ru"><p>научный сотрудник</p></bio><email>savinova.ekaterina96@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5135-0997</contrib-id><name-alternatives><name xml:lang="en"><surname>Voznesenskii</surname><given-names>Vladimir I.</given-names></name><name xml:lang="ru"><surname>Вознесенский</surname><given-names>Владимир Игоревич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), oncologist, obstetrician-gynecologist</p></bio><bio xml:lang="ru"><p>кандидат мед. наук, врач-онколог, акушер-гинеколог</p></bio><email>vlad525@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6336-9900</contrib-id><name-alternatives><name xml:lang="en"><surname>Kostyuk</surname><given-names>Svetlana V.</given-names></name><name xml:lang="ru"><surname>Костюк</surname><given-names>Светлана Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), assistant professor, Head of the Laboratory</p></bio><bio xml:lang="ru"><p>доктор мед. наук, доцент, заведующая лабораторией</p></bio><email>svet-vk@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1732-6870</contrib-id><contrib-id contrib-id-type="spin">6313-9959</contrib-id><name-alternatives><name xml:lang="en"><surname>Sosnova</surname><given-names>Elena A.</given-names></name><name xml:lang="ru"><surname>Соснова</surname><given-names>Елена Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>доктор мед. наук, профессор</p></bio><email>sosnova-elena@inbox.ru</email><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Centre for Medical Genetics</institution></aff><aff><institution xml:lang="ru">Медико-генетический научный центр им. академика Н.П. Бочкова</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Central Research Institute for Epidemiology</institution></aff><aff><institution xml:lang="ru">Центральный научно-исследовательский институт эпидемиологии</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">D.D. Pletnev City Clinical Hospital</institution></aff><aff><institution xml:lang="ru">Городская клиническая больница им. Д.Д. Плетнёва</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-06-16" publication-format="electronic"><day>16</day><month>06</month><year>2023</year></pub-date><volume>10</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>133</fpage><lpage>143</lpage><history><date date-type="received" iso-8601-date="2023-06-16"><day>16</day><month>06</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-06-16"><day>16</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2023,</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-06-16"/></permissions><self-uri xlink:href="https://archivog.com/2313-8726/article/view/497406">https://archivog.com/2313-8726/article/view/497406</self-uri><abstract xml:lang="en"><p><bold><italic>BACKGROUND</italic></bold><bold><italic>:</italic></bold> Reactive oxygen species play important and ambiguous role in carcinogenesis, and local oxidative metabolism may differ significantly from systemic metabolism and determine the processes occurring in tumor tissues.</p> <p><bold><italic>AIM</italic></bold><bold><italic>: </italic></bold>This study aimed to examine the expressions of key oxidative metabolism genes, particularly <italic>CYB</italic><italic>5</italic><italic>R</italic><italic>, </italic><italic>POR</italic><italic>, </italic><italic>NOX</italic><italic>4, </italic><italic>SOD</italic><italic>1, </italic><italic>NF</italic><italic>-κ</italic><italic>B</italic><italic>, </italic>and <italic>NRF</italic><italic>2</italic>, in ovarian neoplasm tissues, and determine cytochrome <italic>b</italic><italic>5</italic> reductase and cytochrome P450 reductase activity, blood neutrophil activity, and antioxidant indices in the blood plasma and peritoneal fluid.</p> <p><bold><italic>MATERIALS</italic></bold> <bold><italic>AND</italic></bold> <bold><italic>METHODS</italic></bold><bold><italic>:</italic></bold> The study included two groups of patients: a study group (<italic>n = </italic>10) with ovarian adenocarcinoma and a comparison group (<italic>n = </italic>6) with benign ovarian neoplasms. The expressions of <italic>CYB</italic><italic>5</italic><italic>R</italic><italic>1, </italic><italic>CYB</italic><italic>5</italic><italic>R</italic><italic>2/</italic><italic>R</italic><italic>4, </italic><italic>CYB</italic><italic>5</italic><italic>R</italic><italic>3, </italic><italic>POR</italic><italic>, </italic><italic>BIRC</italic><italic>3, </italic><italic>NOX</italic><italic>4, </italic><italic>NRF</italic><italic>2, </italic><italic>NF</italic><italic>-κ</italic><italic>B</italic><italic>, </italic><italic>SOD</italic><italic>1, </italic><italic>HMOX</italic><italic>1, </italic>and <italic>BCL</italic><italic>2</italic> genes, cytochrome <italic>b</italic><italic>5</italic> reductase, and cytochrome P450 reductase activity, oxidative activity of blood neutrophils, and antioxidant potential of plasma and peritoneal fluid were evaluated in these two groups of women.</p> <p><bold><italic>RESULTS</italic></bold><bold><italic>: </italic></bold>The expression levels of <italic>CYB</italic><italic>5</italic><italic>R</italic><italic>3</italic> and <italic>BCL</italic><italic>2</italic> were significantly lower in adenocarcinoma tissues. The activities of cytochrome <italic>b</italic><italic>5</italic> reductase and cytochrome P450 reductase increased in the group with adenocarcinoma. On average, the activity of blood neutrophils corresponded to the reference values. For blood plasma, the antioxidant capacity were not different, whereas the antioxidant capacity in the peritoneal fluid increased approximately twofold in ovarian cancer.</p> <p><bold><italic>CONCLUSIONS</italic></bold><bold><italic>:</italic></bold> Significantly increased cytochrome <italic>b</italic><italic>5</italic> reductase activity in adenocarcinoma tissues may be a response to intracellular oxidative stress, whereas <italic>CYB</italic><italic>5</italic><italic>R</italic><italic>3</italic> gene expression may be reduced by a negative feedback mechanism. The activities of cytochrome P450 reductase and its gene change to a lesser extent in the presence of ovarian adenocarcinoma. The oxidative balance in the blood and peritoneal fluid correlated with the tissue expressions of <italic>NF</italic><italic>-κ</italic><italic>B</italic> and <italic>NRF</italic><italic>2</italic>.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>Активные формы кислорода играют важную и неоднозначную роль в канцерогенезе, при этом локальный оксидативный метаболизм может сильно отличаться от системного метаболизма и определять процессы, происходящие в ткани опухоли.</p> <p><bold>Цель исследования</bold> — изучить экспрессию ключевых генов оксидативного метаболизма, в частности генов <italic>CYB</italic><italic>5</italic><italic>R</italic><italic>, </italic><italic>POR</italic><italic>, </italic><italic>NOX</italic><italic>4, </italic><italic>SOD</italic><italic>1, </italic><italic>NF</italic><italic>-κ</italic><italic>B</italic><italic>, </italic><italic>NRF</italic><italic>2</italic>, в тканях новообразований яичника параллельно с определением активности цитохром <italic>b</italic><italic>5</italic>-редуктазы, цитохром Р450-редуктазы, активности нейтрофилов крови и антиоксидантных показателей плазмы крови и перитонеальной жидкости.</p> <p><bold>Материалы и методы.</bold> В исследование включили две группы пациенток: основную группу (<italic>n = </italic>10) с аденокарциномой яичников и группу сравнения (<italic>n = </italic>6) с доброкачественными новообразованиями яичников. У этих двух групп женщин проведено изучение экспрессии генов <italic>CYB</italic><italic>5</italic><italic>R</italic><italic>1, </italic><italic>CYB</italic><italic>5</italic><italic>R</italic><italic>2/</italic><italic>R</italic><italic>4, </italic><italic>CYB</italic><italic>5</italic><italic>R</italic><italic>3, </italic><italic>POR</italic><italic>, </italic><italic>BIRC</italic><italic>3, </italic><italic>NOX</italic><italic>4, </italic><italic>NRF</italic><italic>2, </italic><italic>NF</italic><italic>-</italic>κB<italic>, </italic><italic>SOD</italic><italic>1, </italic><italic>HMOX</italic><italic>1, </italic><italic>BCL</italic><italic>2</italic>, изучение активности цитохром <italic>b</italic><italic>5</italic>-редуктазы и цитохром Р450-редуктазы, а также определение оксидативной активности нейтрофилов крови и антиоксидантного потенциала плазмы и перитонеальной жидкости.</p> <p><bold>Результаты. </bold>Установлено, что экспрессия генов <italic>CYB</italic><italic>5</italic><italic>R</italic><italic>3</italic> и <italic>BCL</italic><italic>2 </italic>была значимо ниже в тканях аденокарциномы. Активность цитохром <italic>b</italic><italic>5</italic>-редуктазы и цитохром Р450-редуктазы оказалась повышена в группе пациенток с аденокарциномой. Активность нейтрофилов крови в среднем соответствовала референтным значениям. Для плазмы крови значения антиоксидантной ёмкости не имели различий, а антиоксидантная ёмкость перитонеальной жидкости в случае рака яичников была увеличена примерно в два раза.</p> <p><bold>Заключение. </bold>Существенно увеличенная активность цитохром <italic>b</italic><italic>5</italic>-редуктазы в тканях аденокарциномы может являться ответом на внутриклеточный оксидативный стресс, при этом экспрессия гена <italic>CYB</italic><italic>5</italic><italic>R</italic><italic>3</italic> может быть снижена по механизму отрицательной обратной связи. Активность цитохром Р450-редуктазы и её гена в меньшей степени изменяется при аденокарциноме яичников. Оксидативный баланс крови и перитонеальной жидкости взаимосвязан с тканевой экспрессией <italic>NF</italic><italic>-κ</italic><italic>B</italic> и <italic>NRF</italic><italic>2</italic>.</p></trans-abstract><trans-abstract xml:lang="zh"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>cytochrome b5 reductase</kwd><kwd>cytochrome P450 reductase</kwd><kwd>NRF2</kwd><kwd>NF-κB</kwd><kwd>blood plasma</kwd><kwd>antioxidant capacity</kwd><kwd>neutrophil activity</kwd><kwd>ovarian cancer</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>цитохром b5-редуктаза</kwd><kwd>цитохром Р450-редуктаза</kwd><kwd>NRF2</kwd><kwd>NF-κB</kwd><kwd>плазма крови</kwd><kwd>антиоксидантная ёмкость</kwd><kwd>активность нейтрофилов</kwd><kwd>рак яичников</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Liu WJ, Huang YX,Wang W, et al. NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells. Cells. 2021;10(7):1647. doi: 10.3390/cells10071647</mixed-citation><mixed-citation xml:lang="ru">Liu W.J., Huang Y.X.,Wang W., et al. NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells // Cells. 2021. Vol. 10, N. 7. P. 1647.doi: 10.3390/cells10071647</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Ding DN, Xie LZ, Shen Y, et al. Insights into the Role of Oxidative Stress in Ovarian Cancer. Oxid Med Cell Longev. 2021;2021:8388258. doi: 10.1155/2021/8388258</mixed-citation><mixed-citation xml:lang="ru">Ding D.N., Xie L.Z., Shen Y., et al. Insights into the Role of Oxidative Stress in Ovarian Cancer // Oxid Med Cell Longev. 2021. Vol. 2021. P. 8388258. doi: 10.1155/2021/8388258</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Strycharz-Dudziak M, Foltyn S, Dworzanski J, et al. Glutathione Peroxidase (GPx) and Superoxide Dismutase (SOD) in Oropharyngeal Cancer Associated with EBV and HPV Coinfection. Viruses. 2020;12(9):1008. doi: 10.3390/v12091008</mixed-citation><mixed-citation xml:lang="ru">Strycharz-Dudziak M., Foltyn S., Dworzanski J., et al. Glutathione Peroxidase (GPx) and Superoxide Dismutase (SOD) in Oropharyngeal Cancer Associated with EBV and HPV Coinfection // Viruses. 2020. Vol. 12, N. 9. P. 1008. doi: 10.3390/v12091008</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Singh N, Baby D, Rajguru JP, et al. Inflammation and cancer. Ann Afr Med. 2019;18(3):121–126. doi: 10.4103/aam.aam_56_18</mixed-citation><mixed-citation xml:lang="ru">Singh N., Baby D., Rajguru J.P., et al. Inflammation and cancer // Ann Afr Med. 2019. Vol. 18, N. 3. P. 121–126. doi: 10.4103/aam.aam_56_18</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Sprooten J, Vankerckhoven A, Vanmeerbeek I, et al. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. J Immunother Cancer. 2021;9(11):e003609. doi: 10.1136/jitc-2021-003609</mixed-citation><mixed-citation xml:lang="ru">Sprooten J., Vankerckhoven A., Vanmeerbeek I., et al. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer // J Immunother Cancer. 2021. Vol. 9, N. 11. P. e003609. doi: 10.1136/jitc-2021-003609</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Elahian F, Sepehrizadeh Z, Moghim B, Mirzaei SA. Human cytochrome b5 reductase: structure, function, and potential applications. Crit Rev Biotechnol. 2014;34(2):134–143.doi: 10.3109/07388551.2012.732031</mixed-citation><mixed-citation xml:lang="ru">Elahian F., Sepehrizadeh Z., Moghim B., Mirzaei S.A. Human cytochrome b5 reductase: structure, function, and potential applications // Crit Rev Biotechnol. 2014. Vol. 34, N. 2. P. 134–143.ьdoi: 10.3109/07388551.2012.732031</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Lund RR, Leth-Larsen R, Caterino TD, et al. NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer. Mol Cell Proteomics. 2015;14(11):2988–2999. doi: 10.1074/mcp.M115.050385</mixed-citation><mixed-citation xml:lang="ru">Lund R.R., Leth-Larsen R., Caterino T.D., et al. NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer // Mol Cell Proteomics. 2015. Vol. 14, N. 11. P. 2988–2999.ьdoi: 10.1074/mcp.M115.050385</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Wisniewska A, Jagiello K, Mazerska Z. NADPH-cytochrome P450 reductase, not only the partner of cytochrome P450. Postepy Biochem. 2009;55(3):272–278.</mixed-citation><mixed-citation xml:lang="ru">Wisniewska A., Jagiello K., Mazerska Z. NADPH-cytochrome P450 reductase, not only the partner of cytochrome P450 // Postepy Biochem. 2009. Vol. 55, N. 3. P. 272–278.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Proskurnina EV, Fedorova MV, Sozarukova MM, et al. Microsomal reductase activity in patients with thyroid neoplasms. Endocrine. 2021;72(3):735–743. doi: 10.1007/s12020-020-02513-z</mixed-citation><mixed-citation xml:lang="ru">Proskurnina E.V., Fedorova M.V., Sozarukova M.M., et al. Microsomal reductase activity in patients with thyroid neoplasms // Endocrine. 2021. Vol. 72, N. 3. P. 735–743,doi: 10.1007/s12020-020-02513-z</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Saunders MP, Patterson AV, Chinje EC, Harris AL, Stratford IJ. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br J Cancer. 2000;82(3):651–656. doi: 10.1054/bjoc.1999.0977</mixed-citation><mixed-citation xml:lang="ru">Saunders M.P., Patterson A.V., Chinje E.C., Harris A.L., Stratford I.J. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line // Br J Cancer. 2000. Vol. 82, N. 3. P. 651–656. doi: 10.1054/bjoc.1999.0977</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. 1995;11(7):1217–1228.</mixed-citation><mixed-citation xml:lang="ru">Eliopoulos A.G., Kerr D.J., Herod J., et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2 // Oncogene. 1995. Vol. 11, N. 7. P. 1217–1228.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Marx D, Binder C, Meden H, et al. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res. 1997;17(3C):2233–2240.</mixed-citation><mixed-citation xml:lang="ru">Marx D., Binder C., Meden H., et al. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer // Anticancer Res. 1997. Vol. 17, N. 3C. P. 2233–2240.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Mano Y, Kikuchi Y, Yamamoto K, et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer. 1999;35(8):1214–1219.doi: 10.1016/s0959-8049(99)00124-0</mixed-citation><mixed-citation xml:lang="ru">Mano Y., Kikuchi Y., Yamamoto K., et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer // Eur J Cancer. 1999. Vol. 35, N. 8. P. 1214–1219.doi: 10.1016/s0959-8049(99)00124-0</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Liang M, Zhao J. Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis. Eur Rev Med Pharmacol Sci. 2018;22(16):5134–5139. doi: 10.26355/eurrev_201808_15708</mixed-citation><mixed-citation xml:lang="ru">Liang M., Zhao J. Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis // Eur Rev Med Pharmacol Sci. 2018. Vol. 22, N. 16. P. 5134–5139. doi: 10.26355/eurrev_201808_15708</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Baekelandt M, Kristensen GB, Nesland JM, Trope CG, Holm R. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol. 1999;17(7):2061.doi: 10.1200/JCO.1999.17.7.2061</mixed-citation><mixed-citation xml:lang="ru">Baekelandt M., Kristensen G.B., Nesland J.M., Trope C.G., Holm R. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer // J Clin Oncol. 1999. Vol. 17, N. 7. P. 2061. doi: 10.1200/JCO.1999.17.7.2061</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Chaudhry P, Srinivasan R, Patel FD. Differential expression of Fas family members and Bcl-2 family members in benign versus malignant epithelial ovarian cancer (EOC) in North Indian population. Mol Cell Biochem. 2012;368(1–2):119–126.doi: 10.1007/s11010-012-1350-7</mixed-citation><mixed-citation xml:lang="ru">Chaudhry P., Srinivasan R., Patel F.D. Differential expression of Fas family members and Bcl-2 family members in benign versus malignant epithelial ovarian cancer (EOC) in North Indian population // Mol Cell Biochem. 2012. Vol. 368, N. 1–2. P. 119–126.doi: 10.1007/s11010-012-1350-7</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Chen C, You F, Wu F, et al. Antiangiogenesis Efficacy of Ethanol Extract from Amomum tsaoko in Ovarian Cancer through Inducing ER Stress to Suppress p-STAT3/NF-kB/IL-6 and VEGF Loop. Evid Based Complement Alternat Med. 2020;2020:2390125.doi: 10.1155/2020/2390125</mixed-citation><mixed-citation xml:lang="ru">Chen C., You F., Wu F., et al. Antiangiogenesis Efficacy of Ethanol Extract from Amomum tsaoko in Ovarian Cancer through Inducing ER Stress to Suppress p-STAT3/NF-kB/IL-6 and VEGF Loop // Evid Based Complement Alternat Med. 2020. Vol. 2020. P. 2390125.doi: 10.1155/2020/2390125</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Chen G, Zhu L, Yang Y, et al. Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis. Technol Cancer Res Treat. 2018;17:1533033818791500.doi: 10.1177/1533033818791500</mixed-citation><mixed-citation xml:lang="ru">Chen G., Zhu L., Yang Y., et al. Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis // Technol Cancer Res Treat. 2018. Vol. 17. P. 1533033818791500.doi: 10.1177/1533033818791500</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Lichtenstein A, Seelig M, Berek J, Zighelboim J. Human neutrophil-mediated lysis of ovarian cancer cells. Blood. 1989;74(2): 805–809.</mixed-citation><mixed-citation xml:lang="ru">Lichtenstein A., Seelig M., Berek J., Zighelboim J. Human neutrophil-mediated lysis of ovarian cancer cells // Blood. 1989. Vol. 74, N. 2. P. 805–809.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Klink M, Jastrzembska K, Nowak M, et al. Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scand J Immunol. 2008;68(3):328–336.doi: 10.1111/j.1365-3083.2008.02139.x</mixed-citation><mixed-citation xml:lang="ru">Klink M., Jastrzembska K., Nowak M., et al. Ovarian cancer cells modulate human blood neutrophils response to activation in vitro // Scand J Immunol. 2008. Vol. 68, N. 3. P. 328–336.doi: 10.1111/j.1365-3083.2008.02139.x</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Tobon-Velasco JC, Cuevas E, Torres-Ramos MA. Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress. CNS Neurol Disord Drug Targets. 2014;13(9):1615–1626.doi: 10.2174/1871527313666140806144831</mixed-citation><mixed-citation xml:lang="ru">Tobon-Velasco J.C., Cuevas E., Torres-Ramos M.A. Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress // CNS Neurol Disord Drug Targets. 2014. Vol. 13, N. 9. P. 1615–1626. doi: 10.2174/1871527313666140806144831</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Van der Wijst MGP, Brown R, Rots MG. Nrf2, the master redox switch: the Achilles’ heel of ovarian cancer? Biochim Biophys Acta. 2014;1846(2):494–509. doi: 10.1016/j.bbcan.2014.09.004</mixed-citation><mixed-citation xml:lang="ru">Van der Wijst M.G.P., Brown R., Rots M.G. Nrf2, the master redox switch: the Achilles’ heel of ovarian cancer? // Biochim Biophys Acta. 2014. Vol. 1846, N. 2. P. 494–509.doi: 10.1016/j.bbcan.2014.09.004</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Cho HY, Kim K, Kim YB, Kim H, No JH. Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival. Int J Gynecol Cancer. 2017;27(3):412–419. doi: 10.1097/IGC.0000000000000908</mixed-citation><mixed-citation xml:lang="ru">Cho H.Y., Kim K., Kim Y.B., Kim H., No J.H. Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival // Int J Gynecol Cancer. 2017. Vol. 27, N. 3. P. 412–419. doi: 10.1097/IGC.0000000000000908</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Huang TT, Hao DL, Wu BN, Mao LL, Zhang J. Uric acid demonstrates neuroprotective effect on Parkinson’s disease mice through Nrf2-ARE signaling pathway. Biochem Biophys Res Commun. 2017;493(4):1443–1449. doi: 10.1016/j.bbrc.2017.10.004</mixed-citation><mixed-citation xml:lang="ru">Huang T.T., Hao D.L., Wu B.N., Mao L.L., Zhang J. Uric acid demonstrates neuroprotective effect on Parkinson’s disease mice through Nrf2-ARE signaling pathway // Biochem Biophys Res Commun. 2017. Vol. 493, N. 4. P. 1443–1449. doi: 10.1016/j.bbrc.2017.10.004</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Lin Y, Xie Y, Hao Z, et al. Protective Effect of Uric Acid on ox-LDL-Induced HUVECs Injury via Keap1-Nrf2-ARE Pathway. J Immunol Res. 2021;2021:5151168. doi: 10.1155/2021/5151168</mixed-citation><mixed-citation xml:lang="ru">Lin Y., Xie Y., Hao Z., et al. Protective Effect of Uric Acid on ox-LDL-Induced HUVECs Injury via Keap1-Nrf2-ARE Pathway // J Immunol Res. 2021. Vol. 2021. P. 5151168.doi: 10.1155/2021/5151168</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Jiang Z, Fletcher NM, Ali-Fehmi R, et al. Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells. Gynecol Oncol. 2011;122(2):418–423. doi: 10.1016/j.ygyno.2011.04.051</mixed-citation><mixed-citation xml:lang="ru">Jiang Z., Fletcher N.M., Ali-Fehmi R., et al. Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells // Gynecol Oncol. 2011. Vol. 122, N. 2. P. 418–423.doi: 10.1016/j.ygyno.2011.04.051</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Ghazy AA, El-Etreby NM, Rashad R, Moussa N. Role of Oxidative Stress in Prognosis of Ovarian Cancer. Egypt J Immunol. 2020;27(2):31–38.</mixed-citation><mixed-citation xml:lang="ru">Ghazy A.A., El-Etreby N.M., Rashad R., Moussa N. Role of Oxidative Stress in Prognosis of Ovarian Cancer // Egypt J Immunol. 2020. Vol. 27, N. 2. P. 31–38.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Senthil K, Aranganathan S, Nalini N. Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin Chim Acta. 2004;339(1–2):27–32. doi: 10.1016/j.cccn.2003.08.017</mixed-citation><mixed-citation xml:lang="ru">Senthil K., Aranganathan S., Nalini N. Evidence of oxidative stress in the circulation of ovarian cancer patients // Clin Chim Acta. 2004. Vol. 339, N. 1–2. P. 27–32. doi: 10.1016/j.cccn.2003.08.017</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Hecht JL, Janikova M, Choudhury R, et al. Labile Heme and Heme Oxygenase-1 Maintain Tumor-Permissive Niche for Endometriosis-Associated Ovarian Cancer. Cancers (Basel). 2022;14(9):2242. doi: 10.3390/cancers14092242</mixed-citation><mixed-citation xml:lang="ru">Hecht J.L., Janikova M., Choudhury R., et al. Labile Heme and Heme Oxygenase-1 Maintain Tumor-Permissive Niche for Endometriosis-Associated Ovarian Cancer // Cancers (Basel). 2022. Vol. 14, N. 9. P. 2242. doi: 10.3390/cancers14092242</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Jing T, Guo Y, Wei Y. Carboxymethylated pachyman induces ferroptosis in ovarian cancer by suppressing NRF1/HO-1 signaling. Oncol Lett. 2022;23(5):161. doi: 10.3892/ol.2022.13281.</mixed-citation><mixed-citation xml:lang="ru">Jing T., Guo Y., Wei Y. Carboxymethylated pachyman induces ferroptosis in ovarian cancer by suppressing NRF1/HO-1 signaling // Oncol Lett. 2022. Vol. 23, N. 5. P. 161. doi: 10.3892/ol.2022.13281.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
